Immunisations Flashcards

1
Q

What are the objectives of immunisation

A

To protect individuals from a disease (either from infection or from mortality)
To protect populations
To achieve herd immunity - to stop transmission
Eradication of disease
Decrease severity of disease - reducing hospitalisation
Indirect protection - vaccinating mother to protect baby e.g. whooping cough
To protect selected high risk groups

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
2
Q

What is the difference between eradication and elimination

A

Elimination: removal from an area (no longer endemic) - but can still get imported cases.
Eradication - no cases

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
3
Q

Difference between vaccination and immunisation

A

Vaccination = to give a vaccine - may not result in immunity
Immunisation - to artificially confer immunity

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
4
Q

2 mechanisms of immunisation

A

Active
Passive

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
5
Q

Different types of vaccines

A

Live unattenuated
Live attenuated
Killed whole organisms
Disrupted toxin
Antigenic components from organisms
Manufactured virus like particles
Conjugated vaccine

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
6
Q

Example of live unattenuated vaccine

A

Original cow pox innoculations - body generates immunity to small pox not just cow pox (and cow pox doesn’t make them that sick)

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
7
Q

Examples of live attenuated vaccines

A

MMR
BCG
Oral Polio vaccine

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
8
Q

Example of killed whole organism vaccine

A

Injectable polio

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
9
Q

Example of disrupted toxin vaccine

A

Tetanus toxoid

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
10
Q

Example of antigenic components from organisms vaccine

A

Flu
Hep B
Covid19

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
11
Q

example of manufactured virus like particles vaccines

A

HPV

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
12
Q

What is a conjugated vaccine

A

combines a weak antigen with a strong antigen as a carrier so that the immune system has a stronger response to the weak antigen
(particularly in vaccines for children e.g. HIB)

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
13
Q

Why is eradication difficult to achieve

A

Expensive
Has to be a global effort
Only works if vaccines stop transmission rather than reducing severity
Needs peace (not war)
Needs political will

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
14
Q

What are nasal vaccines good for

A

Reducing airborne transmission

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
15
Q

What factors effect susceptibility to disease

A

Immunity - previous natural infection or previous immunisation

Age - immature immune systems and waning immunity (the older you get the less able you are to produce a non specific response - rely on memory and targeted response

Immunocompetence - immune deficiency syndromes, immunosuppressive treatments, steroids, intercurrent infection

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
16
Q

Why will 100% personal protection never be achieved with immunisation

A

<100% Vaccine efficacy due to:
- handling
- temperature
- optimal age for vaccination
- Boosters (lack of completing course)
- Optimal dose etc.
- Mutation of pathogen
- effective administration

<100% vaccine uptake due to:
- public perception
- misinformation
- accessibility
- culture
- production - enough
- religion (vaccines containing pork etc.)
- medical conditions/contraindications preventing immunisation

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
17
Q

What does R0 depend on

A

Organism characteristics: infectivity, duration of infectiousness
Population characteristics: Mixing patterns, demographics, population density

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
18
Q

What is the effective reproduction number (R)

A

the average number of secondary infections produced by a typical infective agent.
In a homogenously mixing population where s is the proportion susceptible: R=R0xs

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
19
Q

What is the epidemic threshold?

A

If R>1, the number of cases increases
If R <1, the number of cases decreases
R=1 is the epidemic threshold.
To achieve elimination we need to maintain R<1

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
20
Q

What is the critical proportion susceptible (s*)

A

The threshold at R=1, defines the critical proportion susceptible, s*
1=R0 x s
S* = 1/R0

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
21
Q

What variable effects herd immunity

A

the greater the infectivity (reproductive rate) of a disease, the higher the immunisation rate needed to achieve herd immunity

22
Q

Herd Immunity Threshold (H)

A

H = 1-S*
so
H=1-1/R0
Measles has one of the highest herd immunity thresholds (92-95%) whereas influenza has one of the lowest (33-44%)

23
Q

What is vaccine efficacy (VE)

A

AR (unvaccinated)

x100
(AR = attack rate)

24
Q

Decision making process for deciding whether to implement a new immunisation programme

A
  • Disease burden (is it a PH problem) - no. of cases, morbidity, mortality
  • Is immunisation the best strategy for controlling the disease (is there another way and then analyse cost, benefit, effectiveness, safety, feasibility, practicality of each method compared to immunisation)
  • What will be the net impact of introducing a new vaccine (impact on disease burden - vaccine effectiveness; vaccine safety (adverse effects, monitoring systems, vaccine damage, compensation schemes)
  • How well is our current immunisation programme working? (will introduction of a new vaccine make things better or worse, fit in with current schedule)
  • How much disease will be prevented (depends on age-specific disease burden in relation to age of immunisation, vaccine effectiveness & coverage)
  • what are the possible negative effects of the new vaccination programme? (vaccine risk, possibility of programme errors, risk in strategy, vaccines interfering with each other)
  • what resources are needed
  • what is the impact on public perception (will adding new vaccine damage perception of immunisation)
  • is the vaccine a good investment (cost of introduction - one off and ongoing costs, economic analysis: cost-benefit compared to other interventions, opportunity cost)
25
Q

What to consider when implementing vaccines (short answer)

A
  • Cost benefit analysis
  • demand/need
  • infrastructure
  • acceptability
  • purpose of vaccination
26
Q

What to consider when implementing a new immunisation programme

A
  • Who to vaccinate (depends on aim - to protect vulnerable, contain outbreak or eradicate disease); group with greatest morbidity/mortality; window of opportunity for prevention (e.g. preexposure); optimum effectiveness; vaccine efficacy in different age groups
  • How to implement (Pilots, phased introduction, global immunisation)
  • When to vaccinate (greatest impact on disease burden e.g. seasonal diseases; things to do to maximise uptake e.g. term time if school aged, multiple vaccines for rapid protection of most vulnerable etc.)
27
Q

Examples of international immunisation programmes

A

EPI - expanded programme on immunisation
GPEI - global polio eradication initiative
GAVI (global alliance for vaccines and immunisation)
COVAX

28
Q

Role of WHO for immunisations

A
  • makes recommendations for policy
  • supports less able countries with strategy implementation
  • works through the international health regulations
29
Q

Diphtheria

A

Caused by Corynebacterium diphtheria
Primarily infects the throat and upper airways
Produces a toxin affecting other organs
2 types:
- disease of throat and tonsils
- skin ulcers especially in tropical countries
most cases in unvaccinated children
fatal in 5-10%

30
Q

Tetanus

A

Clostridium tetani
produces a toxin that causes painful muscle contractions, making it hard to open the mouth and swallow (lockjaw)
Neonatal and maternal tetanus = most common & serious
Mortality reducing due to TTCV (tetanus toxoid containing vaccine)
MNTE: Maternal & Neonatal Tetanus Elimination Initiative, launched 1999 (immunisation, clean deliveries & surveillance)

31
Q

Polio

A

Viral. V infectious.
Mostly effects children <5
Person to person spread, mainly faecal-oral or sometimes contaminated food/water
Intestine –> nervous system –> paralysis
1/200 irreversible paralysis. 5-10% die.
Cases dramatically reducing - oral polio vaccine multiple doses for children
in 2020 only Afghanistan and Pakistan were still polio-endemic

32
Q

Measles

A

Viral. Airborne transmission. Prior to vaccine in 1963 major epidemics every 2-3 years. Most deaths = complications –> most common in <5 and >30.
Blindness, encephalitis, severe diarrhoea & dehydration, ear infections, pneumonia
Severe more likely in malnourished, insufficient vitA, immunocompromised (HIV/AIDS etc.)
95% in LICs
Measles vaccines - one of the best buys in PH

33
Q

Haemophilus Influenza B (HiB)

A

Bacterial, transmitted through resp tract.
Severe pneumonia, meningitis etc. <5.
2-3 million serious, 386000 deaths p.a.
Needs prompt lab investigation prior to Abx.
Abx resistance increasing
Vaccine - only PH tool: in >100 countries so far.
Hib conjugate vaccine recommended (available monovalent or combined with DTP and others)

34
Q

Hepatitis B

A

Viral.
Transmission: blood & sex
Life threatening & can lead to chronic liver disease & > death from liver cirrhosis & liver cancer
2billion infected
Vaccine 95% effective preventing infection & chronic consequences
Only given to high risk groups in UK atm.

35
Q

Yellow Fever

A

Caused by flavivirus. Mosquito vector.
Cases severely underreported.
Varies from mild fever –> fatal multi-organ failure
200,000 cases & 30,000 deaths p.a.
Vaccine: life long immunity, used in travellers & outbreak.
Mosquito control programmes - lapsed in some areas

Strategy to Eliminate Yellow fever Epidemic (EYE) by GAVI, WHO, UNICEF etc to face challenging epidemiology, resurgence of mosquitos, increased risk of urban outbreaks and spread. Aims to protect at risk populations, prevent international spread, contain outbreaks rapidly

36
Q

Vaccines at 8 weeks

A

Diphtheria, tetanus, pertussis (whooping cough), polio, Hib, hep B
MenB
Rotavirus

37
Q

Vaccines at 12 weeks

A

Diphtheria, tetanus, pertussis, polio, Hib, hep B
Pneumococcal
Rotavirus

38
Q

Vaccines at 16 weeks

A

Diphtheria, tetanus, pertussis, polio, Hib and hepatitis B
MenB

39
Q

1 year old vaccines

A

Hib, MenC
Pneumococcal
MMR
MenB

40
Q

Eligable children each year from September vaccine

A

Influenza

41
Q

~3 years 4 months vaccines

A

Diphtheria, tetanus, pertussis, polio
MMR

42
Q

Boys and girls aged 12-13 vaccines

A

HPV

43
Q

14 years vaccines

A

Tetanus, diphtheria, polio
Meningococcal A,C,W,Y

44
Q

65 years old vaccine

A

Pneumococcal & Shingles

45
Q

> 65 years annual vaccine

A

influenza

46
Q

70-79 years vaccine

A

shingles

47
Q

Expanded Programme on Immunisation (EPI)

A

Launched following success of smallpox vaccine. Aims to ensure vaccination for all children <1.
Measles, whooping cough, diphtheria, tetanus, polio, TB now also vitamin A, HBsAG B (HepB), Hib, Yellow fever

48
Q

Strategies to achieve global vaccination targets

A

Integrate vaccination with primary healthcare services
Expand vaccination coverage to eligible population
Ensure regular supply of potent vaccines
Strengthen the cold chain
Training & capacity building of health personnel
Promote community participation
Incorporating health education
Ensure logistic support
Monitoring & evaluation
Research

49
Q

What is the vaccine cold chain pathway

A

Need to maintain the same temperature throughout the chain
- Manufacturer
- National storage facility
- Regional hospital
- Health centre
- Vaccination outreach

50
Q

Challenges in implementing vaccination programmes (globally)

A

Cold chain management
Education (public awareness/support, culture, suspicion of the west
Mistrust
Corruption
Cost
Lack of skills in healthcare workers
Lack of training
Supply chain
Access - vaccination on a market day, difficult to access communities etc

51
Q

6 Objectives of the global vaccine action plan

A
  1. All countries commit to immunisation as a priority
  2. individuals & communities understand the value of vaccines & demand them as their right and responisbility
  3. benefits of immunisation equitably extended to all people
  4. strengthen immunisation systems as part of a well functioning health system
  5. ensure immunisation programmes have sustainable access to predictable funding, supply, & innovative technologies
  6. Country, regional, and global research and development innovations maximise benefits of immunisation.
52
Q
A